Research Articles
Research articles concerning NAFLD are extracted from PubMed. For each individual article, related therapeutic strategies, targets, drugs and associated diseases in NAFLDkb are presented with knowledge graphs.
stats1
stats2
stats3
stats4
Search for:
diabetes mellitus4971 records.
| Article ID | PMID | Source | Title | Publish Year | |
|---|---|---|---|---|---|
| A05345 | 33293347 | Diabetes Care | Hepatic Insulin Resistance Is Not Pathway Selective in Humans With Nonalcoholic Fatty Liver Disease. | 2020 | Details |
| A05347 | 33291863 | Clin Mol Hepatol | The role of the gut microbiome and diet in the pathogenesis of non-alcoholic fatty liver disease. | 2020 | Details |
| A05356 | 33284184 | Am J Gastroenterol | Role of Noninvasive Tests in Clinical Gastroenterology Practices to Identify Patients With Nonalcoholic Steatohepatitis at High Risk of Adverse Outcomes: Expert Panel Recommendations. | 2021 | Details |
| A05361 | 33282899 | Front Nutr | Corrigendum: PTEN: A Thrifty Gene That Causes Disease in Times of Plenty? | 2020 | Details |
| A05362 | 33282271 | Food Sci Nutr | Protective effect of celastrol on type 2 diabetes mellitus with nonalcoholic fatty liver disease in mice. | 2020 | Details |
| A05373 | 33279452 | Clin Res Hepatol Gastroenterol | Transient elastography through controlled attenuated parameter assisting the stratification of cardiovascular disease risk in NAFLD patients. | 2020 | Details |
| A05374 | 33278735 | Curr Opin Pharmacol | The role of the liver in the modulation of glucose and insulin in non alcoholic fatty liver disease and type 2 diabetes. | 2020 | Details |
| A05375 | 33278596 | Biochim Biophys Acta Mol Cell Biol Lipids | Systems biology approaches to study lipidomes in health and disease. | 2020 | Details |
| A05390 | 33273703 | Sci Rep | Saroglitazar in patients with non-alcoholic fatty liver disease and diabetic dyslipidemia: a prospective, observational, real world study. | 2020 | Details |
| A05400 | 33270482 | Expert Rev Gastroenterol Hepatol | A single-letter change in an acronym: signals, reasons, promises, challenges, and steps ahead for moving from NAFLD to MAFLD. | 2020 | Details |
| A05404 | 33269259 | World J Clin Cases | Essential phospholipids for nonalcoholic fatty liver disease associated with metabolic syndrome: A systematic review and network meta-analysis. | 2020 | Details |
| A05406 | 33269025 | J Med Biochem | Is endocan a novel potential biomarker of liver steatosis and fibrosis? | 2020 | Details |
| A05413 | 33268509 | Sci Transl Med | Transcriptomic profiling across the nonalcoholic fatty liver disease spectrum reveals gene signatures for steatohepatitis and fibrosis. | 2020 | Details |
| A05415 | 33268450 | BMJ Open Diabetes Res Care | SGLT2 inhibitors in patients with type 2 diabetes with non-alcoholic fatty liver diseases: an umbrella review of systematic reviews. | 2020 | Details |
| A05425 | 33261044 | Int J Mol Sci | Soluble Endoglin as a Potential Biomarker of Nonalcoholic Steatohepatitis (NASH) Development, Participating in Aggravation of NASH-Related Changes in Mouse Liver. | 2020 | Details |
| A05430 | 33259845 | J Hepatol | Early changes in hepatic energy metabolism and lipid content in recent-onset type 1 and 2 diabetes mellitus. | 2020 | Details |
| A05451 | 33252454 | Am J Gastroenterol | A Sequential Algorithm Combining ADAPT and Liver Stiffness Can Stage Metabolic-Associated Fatty Liver Disease in Hospital-Based and Primary Care Patients. | 2021 | Details |
| A05456 | 33250172 | J Pediatr | The Prevalence of Nonalcoholic Fatty Liver Disease and Its Risk Factors in Children and Young Adults with Type 1 Diabetes Mellitus. | 2020 | Details |
| A05474 | 33246008 | Metabolism | Moderate alcohol consumption is associated with advanced fibrosis in non-alcoholic fatty liver disease and shows a synergistic effect with type 2 diabetes mellitus. | 2020 | Details |
| A05476 | 33244871 | J Diabetes Investig | Decreased plasma n6 : n3 polyunsaturated fatty acids ratio interacting with high C-peptide promotes non-alcoholic fatty liver disease in type 2 diabetes patients. | 2020 | Details |
| A05485 | 33236464 | Diabetes Obes Metab | Metformin dose increase versus added linagliptin in non-alcoholic fatty liver disease and type 2 diabetes: An analysis of the J-LINK study. | 2020 | Details |
| A05488 | 33235477 | Diabetes Metab Syndr Obes | Elevated TPOAb is a Strong Predictor of Autoimmune Development in Patients of Type 2 Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease: A Case-Control Study. | 2020 | Details |
| A05490 | 33235107 | Medicine (Baltimore) | Usefulness of controlled attenuation parameter and liver stiffness measurement for detecting increased arterial stiffness in asymptomatic populations in China. | 2020 | Details |
| A05494 | 33234342 | Clin Nutr | Mediterranean diet is inversely associated with steatosis and fibrosis and decreases ten-year diabetes and cardiovascular risk in NAFLD subjects: Results from the ATTICA prospective cohort study. | 2020 | Details |
| A05506 | 33225408 | Obes Surg | Are We Ready for Bariatric Surgery in a Liver Transplant Program? A Meta-Analysis. | 2020 | Details |
| A05507 | 33224584 | Am J Cardiovasc Dis | Sex differences in cardiovascular diseases and associated risk factors in non-alcoholic steatohepatitis. | 2020 | Details |
| A05514 | 33220492 | Mol Metab | Nonalcoholic fatty liver disease (NAFLD) from pathogenesis to treatment concepts in humans. | 2020 | Details |
| A05522 | 33219985 | Indian J Gastroenterol | Association between anti-acid therapies and advanced fibrosis in type 2 diabetics with biopsy-proven non-alcoholic fatty liver disease. | 2020 | Details |
| A05524 | 33219119 | BMJ Open Diabetes Res Care | Role of ceramide-to-dihydroceramide ratios for insulin resistance and non-alcoholic fatty liver disease in humans. | 2020 | Details |
| A05530 | 33217178 | Liver Transpl | Nonalcoholic Fatty Liver Disease and Diabetes Mellitus Are Associated With Post-Transjugular Intrahepatic Portosystemic Shunt Renal Dysfunction: An Advancing Liver Therapeutic Approaches Group Study. | 2021 | Details |
| A05532 | 33217052 | J Gastroenterol Hepatol | A review of non-alcoholic fatty liver disease in non-obese and lean individuals. | 2020 | Details |
| A05535 | 33216087 | Food Funct | Amelioration of non-alcoholic fatty liver disease by sodium butyrate is linked to the modulation of intestinal tight junctions in db/db mice. | 2020 | Details |
| A05562 | 33205261 | Curr Gastroenterol Rep | Endobariatrics and Metabolic Endoscopy: Can We Solve the Obesity Epidemic with Our Scope? | 2020 | Details |
| A05582 | 33200017 | World J Hepatol | PNPLA3 and TM6SF2 polymorphisms in Brazilian patients with nonalcoholic fatty liver disease. | 2020 | Details |
| A05594 | 33195636 | World J Clin Cases | Relationship between non-alcoholic fatty liver disease and coronary heart disease. | 2020 | Details |
| A05600 | 33194172 | Ther Adv Endocrinol Metab | The relation between serum adipose differentiation-related protein and non-alcoholic fatty liver disease in type 2 diabetes mellitus. | 2020 | Details |
| A05615 | 33187255 | Cells | Significance of Simple Steatosis: An Update on the Clinical and Molecular Evidence. | 2020 | Details |
| A05617 | 33186794 | Biomed Pharmacother | Therapeutic effect of berberine on metabolic diseases: Both pharmacological data and clinical evidence. | 2020 | Details |
| A05619 | 33186403 | PLoS One | Nineteen-year prognosis in Japanese patients with biopsy-proven nonalcoholic fatty liver disease: Lean versus overweight patients. | 2020 | Details |
| A05621 | 33186123 | Aging (Albany NY) | The nuclear and cytoplasmic roles of miR-320 in non-alcoholic fatty liver disease. | 2020 | Details |
| A05624 | 33185364 | N Engl J Med | A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis. | 2020 | Details |
| A05635 | 33180143 | Eur J Nutr | A bridge for short-chain fatty acids to affect inflammatory bowel disease, type 1 diabetes, and non-alcoholic fatty liver disease positively: by changing gut barrier. | 2020 | Details |
| A05637 | 33179890 | Am Fam Physician | Nonalcoholic Fatty Liver Disease: Common Questions and Answers on Diagnosis and Management. | 2020 | Details |
| A05640 | 33178812 | Ann Transl Med | Diabetes and carotid artery disease: a narrative review. | 2020 | Details |
| A05646 | 33176658 | Curr Diabetes Rev | Dipeptidyl Peptidase IV Inhibitors for Nonalcoholic Fatty Liver Disease - Systematic Review and Metanalysis. | 2021 | Details |
| A05662 | 33169375 | Br J Pharmacol | Exploiting oxidized lipids and the lipid-binding GPCRs against cardiometabolic diseases. | 2020 | Details |
| A05676 | 33163950 | JHEP Rep | NAFLD and liver transplantation: Disease burden, current management and future challenges. | 2020 | Details |
| A05683 | 33160101 | Mol Metab | Genetic and epigenetic factors determining NAFLD risk. | 2020 | Details |
| A05691 | 33155659 | Int J Mol Med | Role of Asxl2 in non‑alcoholic steatohepatitis‑related hepatocellular carcinoma developed from diabetes. | 2020 | Details |
| A05705 | 33148902 | J Med Invest | Long-term empagliflozin therapy improves levels of hepatic fibrosis marker in patients with non-alcoholic fatty liver disease complicated by type 2 diabetes mellitus. | 2020 | Details |
| A05706 | 33148171 | BMC Gastroenterol | Non-invasive predictors of prognosis of Asian patients with histopathologically-confirmed lean nonalcoholic fatty liver disease. | 2020 | Details |
| A05720 | 33143628 | Curr Diabetes Rev | Hepatic Mediators of Lipid Metabolism and Ketogenesis: Focus on Fatty Liver and Diabetes. | 2021 | Details |
| A05739 | 33137486 | Clin Gastroenterol Hepatol | Impact of the New Definition of Metabolic Associated Fatty Liver Disease on the Epidemiology of the Disease. | 2020 | Details |
| A05743 | 33135331 | J Diabetes Investig | Mean and visit-to-visit variability of glycated hemoglobin, and the risk of non-alcoholic fatty liver disease. | 2020 | Details |
| A05744 | 33134908 | JHEP Rep | Hepatic miR-192-3p reactivation alleviates steatosis by targeting glucocorticoid receptor. | 2020 | Details |
| A05747 | 33134485 | Transplant Direct | Effect of Nonalcoholic Fatty Liver Disease and Metabolic Risk Factors on Waitlist Outcomes in Patients With Hepatocellular Carcinoma. | 2020 | Details |
| A05748 | 33133572 | Food Sci Nutr | Alleviative effect of Ruellia tuberosa L. on NAFLD and hepatic lipid accumulation via modulating hepatic de novo lipogenesis in high-fat diet plus streptozotocin-induced diabetic rats. | 2020 | Details |
| A05758 | 33131199 | J Diabetes Investig | Favorable effect of sodium-glucose cotransporter 2 inhibitor, dapagliflozin, on non-alcoholic fatty liver disease compared with pioglitazone. | 2020 | Details |
| A05790 | 33116709 | Diabetes Metab Syndr Obes | Relationship Between Gallstone Disease and Cardiometabolic Risk Factors in Elderly People with Non-Alcoholic Fatty Liver Disease. | 2020 | Details |
| A05791 | 33116702 | Diabetes Metab Syndr Obes | Effect of Saxagliptin, a Dipeptidyl Peptidase 4 Inhibitor, on Non-Alcoholic Fatty Liver Disease. | 2020 | Details |
| A05793 | 33115209 | Diabetes Metab J | Nonalcoholic Fatty Liver Disease: A Drug Revolution Is Coming. | 2020 | Details |
| A05812 | 33110165 | Sci Rep | Current NAFLD guidelines for risk stratification in diabetic patients have poor diagnostic discrimination. | 2020 | Details |
| A05832 | 33103454 | Am J Physiol Endocrinol Metab | GPR40 deficiency is associated with hepatic FAT/CD36 upregulation, steatosis, inflammation, and cell injury in C57BL/6 mice. | 2020 | Details |
| A05840 | 33102794 | Endocrinol Diabetes Metab | The metabolic basis of nonalcoholic steatohepatitis. | 2020 | Details |
| A05843 | 33102775 | JGH Open | Determining whether the effect of liraglutide on non-alcoholic fatty liver disease depends on reductions in the body mass index. | 2020 | Details |
| A05845 | 33102751 | JGH Open | Screening and follow-up of chronic liver diseases with understanding their etiology in clinics and hospitals. | 2020 | Details |
| A05847 | 33102495 | Front Med (Lausanne) | miRNA Dysregulation in the Development of Non-Alcoholic Fatty Liver Disease and the Related Disorders Type 2 Diabetes Mellitus and Cardiovascular Disease. | 2020 | Details |
| A05848 | 33102399 | Can J Gastroenterol Hepatol | Characteristics of NAFLD Based on Hypopituitarism. | 2020 | Details |
| A05867 | 33095789 | PLoS One | Serum zinc level and hepatic fibrosis in patients with nonalcoholic fatty liver disease. | 2020 | Details |
| A05872 | 33093663 | Nat Rev Gastroenterol Hepatol | Nonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors. | 2020 | Details |
| A05876 | 33092030 | Int J Mol Sci | Accumulation of 8-hydroxydeoxyguanosine, L-arginine and Glucose Metabolites by Liver Tumor Cells Are the Important Characteristic Features of Metabolic Syndrome and Non-Alcoholic Steatohepatitis-Associated Hepatocarcinogenesis. | 2020 | Details |
| A05887 | 33088301 | J Res Med Sci | Relationships between severity of steatosis with glycemic control and carotid intima-media thickness among diabetic patients with ischemic heart disease. | 2020 | Details |
| A05894 | 33084982 | Acta Diabetol | Association of 1-deoxy-sphingolipids with steatosis but not steatohepatitis nor fibrosis in non-alcoholic fatty liver disease. | 2020 | Details |
| A05895 | 33083497 | J Immunol Res | Integrative Analyses of Genes Associated with Fulminant Type 1 Diabetes. | 2020 | Details |
| A05917 | 33076386 | Biomolecules | Metabolic Functions of G Protein-Coupled Receptors in Hepatocytes-Potential Applications for Diabetes and NAFLD. | 2020 | Details |
| A05920 | 33075820 | J Clin Endocrinol Metab | Adolescent Nonalcoholic Fatty Liver Disease and Type 2 Diabetes in Young Adulthood. | 2021 | Details |
| A05923 | 33075504 | Diabetes Metab | Lean non-alcoholic fatty liver disease and risk of incident diabetes in a euglycaemic population undergoing health check-ups: A cohort study. | 2020 | Details |
| A05941 | 33069882 | Clin Gastroenterol Hepatol | Expert Panel Review on Nonalcoholic Fatty Liver Disease in Persons With Human Immunodeficiency Virus. | 2020 | Details |
| A05951 | 33065588 | Am J Gastroenterol | Risk Factor Profiles Can Distinguish Esophageal Adenocarcinoma From Barrett's Esophagus. | 2021 | Details |
| A05972 | 33057854 | Curr Diab Rep | Tissue-Specific Fructose Metabolism in Obesity and Diabetes. | 2020 | Details |
| A05973 | 33055335 | Wiad Lek | APOPTOTIC PROCESSES' RESEARCH ON THE MODEL OF TYPE 2 DIABETES MELLITUS ON OBESITY'S BACKGROUND UNDER THE INFLUENCE OF DENSE BEAN EXTRACT. | 2020 | Details |
| A05974 | 33055315 | Rom J Intern Med | Association between serum interleukin (IL)-12 level and severity of non-alcoholic fatty liver disease (NAFLD). | 2021 | Details |
| A05980 | 33053793 | Diagnostics (Basel) | Clinical and Biochemical Predictors of Nonalcoholic Fatty Liver Disease among Type 2 Diabetes Mellitus Patients at Primary Health Care Level in South Western Saudi Arabia. | 2020 | Details |
| A05990 | 33049948 | Metabolites | What's Past Is Prologue: History of Nonalcoholic Fatty Liver Disease. | 2020 | Details |
| A05998 | 33045403 | Contemp Clin Trials | The European NAFLD Registry: A real-world longitudinal cohort study of nonalcoholic fatty liver disease. | 2020 | Details |
| A06005 | 33039693 | Contemp Clin Trials | Semaglutide for the treatment of non-alcoholic steatohepatitis: Trial design and comparison of non-invasive biomarkers. | 2020 | Details |
| A06022 | 33036939 | Surg Obes Relat Dis | Recent advances in the mechanisms underlying the beneficial effects of bariatric and metabolic surgery. | 2020 | Details |
| A06026 | 33036179 | J Clin Med | One Year's Treatment with the Glucagon-Like Peptide 1 Receptor Agonist Liraglutide Decreases Hepatic Fat Content in Women with Nonalcoholic Fatty Liver Disease and Prior Gestational Diabetes Mellitus in a Randomized, Placebo-Controlled Trial. | 2020 | Details |
| A06027 | 33035599 | Diabetes Res Clin Pract | Liraglutide or insulin glargine treatments improves hepatic fat in obese patients with type 2 diabetes and nonalcoholic fatty liver disease in twenty-six weeks: A randomized placebo-controlled trial. | 2020 | Details |
| A06034 | 33033564 | World J Hepatol | Clinical implications, diagnosis, and management of diabetes in patients with chronic liver diseases. | 2020 | Details |
| A06039 | 33031970 | Ann Hepatol | Latin American Association for the study of the liver (ALEH) practice guidance for the diagnosis and treatment of non-alcoholic fatty liver disease. | 2020 | Details |
| A06044 | 33030804 | J Diabetes Investig | Association of the Non-Alcoholic Fatty Liver Disease Fibrosis Score with subclinical myocardial remodeling in patients with type 2 diabetes: A cross-sectional study in China. | 2021 | Details |
| A06051 | 33027714 | Pharmacol Res | FATP2-targeted therapies - A role beyond fatty liver disease. | 2020 | Details |
| A06054 | 33027082 | Am J Gastroenterol | Effects of Statin Use on the Development and Progression of Nonalcoholic Fatty Liver Disease: A Nationwide Nested Case-Control Study. | 2021 | Details |
| A06059 | 33025153 | Abdom Radiol (NY) | Liver fat quantification: where do we stand? | 2020 | Details |
| A06065 | 33024131 | Sci Rep | Characterization of two types of intranuclear hepatocellular inclusions in NAFLD. | 2020 | Details |
| A06073 | 33016540 | Aliment Pharmacol Ther | Patterns and predictors of mortality and disease progression among patients with non-alcoholic fatty liver disease. | 2020 | Details |
| A06074 | 33015726 | Curr Diab Rep | Role of Agents for the Treatment of Diabetes in the Management of Nonalcoholic Fatty Liver Disease. | 2020 | Details |
| A06087 | 33011499 | Diabetes Metab Syndr | Comparative effectiveness of glucagon-like peptide-1 receptor agonists versus dipeptidyl peptidase-4 inhibitors on noninvasive indices of hepatic steatosis and fibrosis in patients with type 2 diabetes mellitus. | 2020 | Details |
| A06093 | 33010191 | Diabetes Metab Res Rev | Effects of sodium-glucose co-transporter 2 inhibitors on liver parameters and steatosis: A meta-analysis of randomized clinical trials. | 2020 | Details |